STRATOS 1 and 2: considerations in clinical trial design for a fully human monoclonal antibody in severe asthma

New therapies are being developed to target proinflammatory mediators thought to be involved in the pathophysiology of severe asthma. Tralokinumab is an investigational fully human monoclonal antibody that specifically blocks binding of IL-13 to its receptors. Here, we describe the background leading to the design of two Phase III trials, STRATOS 1 and 2 (NCT02161757 and NCT02194699), which aim to provide confirmatory evidence of the efficacy and safety of tralokinumab in patients with asthma that is uncontrolled despite treatment with inhaled corticosteroids and long-acting β2-agonists. These trials will also confirm the validity of periostin and DPP-4, identified in a prior Phase IIb study (NCT01402986), as predictors of an enhanced response to tralokinumab.

[1]  P. O'Byrne,et al.  Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. , 2015, The Lancet. Respiratory medicine.

[2]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[3]  G. Rodrigo,et al.  What is the role of tiotropium in asthma?: a systematic review with meta-analysis. , 2015, Chest.

[4]  Y. Nakano,et al.  Using exhaled nitric oxide and serum periostin as a composite marker to identify severe/steroid-insensitive asthma. , 2014, American journal of respiratory and critical care medicine.

[5]  Tom Doel,et al.  Computational modeling of the obstructive lung diseases asthma and COPD , 2014, Journal of Translational Medicine.

[6]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[7]  Kian Fan Chung,et al.  Defining Phenotypes in Asthma: A Step Towards Personalized Medicine , 2014, Drugs.

[8]  Christopher R. Gignoux,et al.  Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease. , 2014, The Journal of allergy and clinical immunology.

[9]  R. Maciuca,et al.  Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials , 2014 .

[10]  R. Townley,et al.  Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma , 2014, Expert opinion on biological therapy.

[11]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[12]  J. Corren.  Role of Interleukin-13 in Asthma , 2013, Current Allergy and Asthma Reports.

[13]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[14]  M. Caruso,et al.  Disabling inflammatory pathways with biologics and resulting clinical outcomes in severe asthma , 2013, Expert opinion on biological therapy.

[15]  J. Matthews,et al.  Redefining approaches to asthma: developing targeted biologic therapies. , 2013, Advances in pharmacology.

[16]  M. Holtzman,et al.  IL-13-induced airway mucus production is attenuated by MAPK13 inhibition. , 2012, The Journal of clinical investigation.

[17]  Monica Kraft,et al.  IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. , 2012, The Journal of allergy and clinical immunology.

[18]  S. Mosesova,et al.  Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. , 2011, The Journal of allergy and clinical immunology.

[19]  C. Brightling,et al.  A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma , 2012, European Respiratory Journal.

[20]  Frank Koentgen,et al.  Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma , 2012, British journal of pharmacology.

[21]  S. Holgate.  Trials and tribulations in identifying new biologic treatments for asthma. , 2012, Trends in immunology.

[22]  Robert A Silverman,et al.  Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. , 2012, The Journal of allergy and clinical immunology.

[23]  Yuichiro J Suzuki,et al.  Oxidant signaling for interleukin-13 gene expression in lung smooth muscle cells. , 2012, Free radical biology & medicine.

[24]  M. Miwa,et al.  Interleukin-13-induced activation of signal transducer and activator of transcription 6 is mediated by an activation of Janus kinase 1 in cultured human bronchial smooth muscle cells , 2012 .

[25]  S. Gupta,et al.  Computed tomography scans in severe asthma: utility and clinical implications , 2012, Current opinion in pulmonary medicine.

[26]  Y. Chiba,et al.  Interleukin-13-induced activation of signal transducer and activator of transcription 6 is mediated by an activation of Janus kinase 1 in cultured human bronchial smooth muscle cells , 2012, Pharmacological reports : PR.

[27]  Pascal Barbry,et al.  Distinct epithelial gene expression phenotypes in childhood respiratory allergy , 2011, European Respiratory Journal.

[28]  Nicola A Hanania,et al.  Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.

[29]  D. Price,et al.  Leukotriene antagonists as first-line or add-on asthma-controller therapy. , 2011, The New England journal of medicine.

[30]  W. Busse,et al.  Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy , 2011, Annals of Internal Medicine.

[31]  L. Boulet,et al.  Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. , 2011, American journal of respiratory and critical care medicine.

[32]  E. R. Sutherland,et al.  Tiotropium bromide step-up therapy for adults with uncontrolled asthma. , 2010, The New England journal of medicine.

[33]  T. Lasserson,et al.  Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. , 2010, The Cochrane database of systematic reviews.

[34]  S. Agee,et al.  Analytical validation of a highly sensitive microparticle-based immunoassay for the quantitation of IL-13 in human serum using the Erenna immunoassay system. , 2009, Journal of immunological methods.

[35]  Salman Siddiqui,et al.  IL-13 expression by blood T cells and not eosinophils is increased in asthma compared to non-asthmatic eosinophilic bronchitis , 2009, BMC pulmonary medicine.

[36]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.

[37]  C. Morimoto,et al.  Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. , 2008, Trends in immunology.

[38]  S. Wenzel,et al.  IL‐13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[39]  A Simon Pickard,et al.  Use of a preference-based measure of health (EQ-5D) in COPD and asthma. , 2008, Respiratory medicine.

[40]  I. Pavord,et al.  Increased sputum and bronchial biopsy IL-13 expression in severe asthma. , 2008, The Journal of allergy and clinical immunology.

[41]  E. Bleecker,et al.  Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[42]  J. Stankova,et al.  Interleukin-4 and Interleukin-13 Enhance Human Bronchial Smooth Muscle Cell Proliferation , 2008, International Archives of Allergy and Immunology.

[43]  Yee Hwa Yang,et al.  Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids , 2007, Proceedings of the National Academy of Sciences.

[44]  C. Lam,et al.  Increased Expression of Plasma and CD4+ T Lymphocyte Costimulatory Molecule CD26 in Adult Patients with Allergic Asthma , 2007, Journal of Clinical Immunology.

[45]  X. Badia,et al.  Asthma control in patients with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: a retrospective observational study , 2007, Current medical research and opinion.

[46]  J. Ceuppens,et al.  Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients , 2006, Thorax.

[47]  M. Kondo,et al.  Elimination of IL-13 reverses established goblet cell metaplasia into ciliated epithelia in airway epithelial cell culture. , 2006, Allergology international : official journal of the Japanese Society of Allergology.

[48]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[49]  I. Pavord,et al.  Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. , 2004, The Journal of allergy and clinical immunology.

[50]  D. Price,et al.  Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma , 2003, Thorax.

[51]  Brigit VanGraafeiland,et al.  National Asthma Education and Prevention Program. , 2002, The Nurse practitioner.

[52]  N. Thomson,et al.  Immuno‐regulatory cytokines in asthma: IL‐15 and IL‐13 in induced sputum , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[53]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[54]  R. Hubbard,et al.  Adverse effects of oral corticosteroids in relation to dose in patients with lung disease , 2001, Thorax.

[55]  V. Casolaro,et al.  Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. , 2001, American journal of respiratory cell and molecular biology.

[56]  F. Symon,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Interleukin-13 induces PSGL-1/P–selectin–dependent adhesion of eosinophils, , 2022 .

[57]  T. Casale,et al.  Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[58]  G H Guyatt,et al.  Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.

[59]  A. Buist,et al.  Validation of a standardized version of the Asthma Quality of Life Questionnaire. , 1999, Chest.

[60]  R. Homer,et al.  Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. , 1999, The Journal of clinical investigation.

[61]  T. Mosmann,et al.  Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. , 1999, Journal of immunology.

[62]  D B Corry,et al.  Requirement for IL-13 independently of IL-4 in experimental asthma. , 1998, Science.

[63]  S. Durham,et al.  Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. , 1997, The Journal of allergy and clinical immunology.

[64]  R. Martin,et al.  Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. , 1997, American journal of respiratory and critical care medicine.

[65]  T. Kotsimbos,et al.  Interleukin-13 and interleukin-4 are coexpressed in atopic asthma. , 1996, Proceedings of the Association of American Physicians.

[66]  R. Coffman,et al.  IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. , 1995, Journal of immunology.